相关实验视频
Updated: May 26, 2025
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
78
血阿尔茨海默病生物标志物与发生异常粉样蛋白 (PET) 的关系
Petrice M Cogswell1, Heather J Wiste2, Stephen D Weigand2
1Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 24, 2025
概括
血生物标志物,包括百分比酸化tau 217 (%p-tau217),可以预测进展到异常的粉样蛋白PET扫描. 这些发现可能有助于识别用于阿尔茨海默病预防试验的个体.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 临床试验 临床试验
背景情况:
- 关于使用血生物标志物预测异常的粉样质正子发射断层扫描 (PET) 的数据有限.
- 这项研究评估了血阿尔茨海默病 (AD) 生物标志物,用于预测最初阴性个体的粉样蛋白PET进展.
研究的目的:
- 评估基线血AD生物标志物与从粉样蛋白PET负 (A-) 到粉样蛋白PET阳性 (A+) 的进展之间的关联.
- 为了确定血生物标志物与粉样蛋白PET随时间变化的速率之间的关系.
主要方法:
- 包括来自梅奥诊所衰老研究的290名认知不损害的参与者,他们最初是粉样蛋白PET负 (A-).
- 估计了基线血生物标志物 (粉样蛋白β 42/40,%p-tau217,粉样蛋白概率评分2) 与A-到A+进展和年度粉样蛋白PET变化率的相关性.
主要成果:
- %p-tau217的四分位数间范围的增加与A-到A+进展的1.38倍增加的危险相关 (P < 0.001) 以及粉样蛋白PET变化的0.50百分位/年增加 (P = 0.007).
- 粉样蛋白β 42/40和粉样蛋白概率评分2显示,与进展和PET变化的关联较弱.
- 年龄和无脂蛋白E ε4载体性也是显著的预测因素.
结论:
- 血%p-tau217显示出作为查工具的潜力,以识别可能从正常到异常的粉样蛋白 (PET) 进步的个体.
- 这些血生物标志物可能有助于丰富阿尔茨海默病初级预防试验的参与者选择.
相关概念视频
01:26Alzheimer's Disease: Overview
425
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
425
01:22Alzheimer's Disease: Treatment
149
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
149
03:03Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K